Academic Background and Problem Statement Epithelial Ovarian Cancer (EOC) remains one of the leading causes of death among gynecologic malignancies. Although the incorporation of molecularly targeted therapies, such as bevacizumab and PARP inhibitors, has improved Progression-Free Survival (PFS) and, in some cases, Overall Survival (OS), many patie...